Novel HIF-1α inhibitor CDMP-TQZ for cancer therapy

被引：7

作者：

Chu, Po-Chen ^{[1
,2
,3
]}

Wu, Yu-Chieh ^{[4
]}

Chen, Chien-Yu ^{[4
]}

Hung, Yu-Syuan ^{[4
]}

Chang, Chih-Shiang ^{[3
,4
]}

机构：

[1] China Med Univ, Dept Cosmeceut, Taichung 40402, Taiwan

[2] China Med Univ, Grad Inst Cosmeceut, Taichung 40402, Taiwan

[3] China Med Univ, Drug Dev Ctr, Taichung 40402, Taiwan

[4] China Med Univ, Sch Pharm, Coll Pharm, Taichung 40402, Taiwan

来源：

FUTURE MEDICINAL CHEMISTRY | 2021年 / 13卷 / 12期

关键词：

anticancer agents; hypoxia-inducible factor-1; tetrahydroquinolines;

D O I：

10.4155/fmc-2020-0307

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Aim: Tumor cells adapt to hypoxic microenvironments by releasing the key transcription factor HIF-1 alpha, which promotes angiogenesis, glycolytic phenotype, metastasis and erythropoiesis, allowing proliferation amid low oxygen levels. Therefore, therapeutic targeting of HIF-1 alpha represents a viable strategy for cancer therapy. Methods & Results: The authors synthesized a series of novel tetrahydroquinazoline derivatives in six steps and demonstrated that their development had a unique ability to suppress HIF-1 alpha expression through proteasomal degradation. Conclusion: Among these compounds, CDMP-TQZ (8bf) exhibited the highest antiproliferative potency in human cancer cells, in part through downregulation of HIF-1 alpha.

引用

收藏

页码：1057 / 1072

页数：16

相关论文

共 35 条

[1] Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/AKT/mTOR Pathway in Cancer [J].

Agani, Faton ;

Jiang, Bing-Hua .

CURRENT CANCER DRUG TARGETS, 2013, 13 (03) :245-251

[2] Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors [J].

An, Hongchan ;

Kim, Nam-Jung ;

Jung, Jong-Wha ;

Jang, Hannah ;

Park, Jong-Wan ;

Suh, Young-Ger .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (21) :6297-6300

[3] The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth [J].

Ban, Hyun Seung ;

Kim, Bo-Kyung ;

Lee, Hongsub ;

Kim, Hwan Mook ;

Harmalkar, Dipesh ;

Nam, Miso ;

Park, Song-Kyu ;

Lee, Kiho ;

Park, Joon-Tae ;

Kim, Inhyub ;

Lee, Kyeong ;

Hwang, Geum-Sook ;

Won, Misun .

CELL DEATH & DISEASE, 2017, 8 :e2843-e2843

[4]

Brahimi-Horn Christiane, 2006, Bull Cancer, V93, pE73

[5]

Cho Daniel, 2009, P267, DOI 10.1007/978-1-59745-332-5_11

[6] PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts [J].

De Santis, Maria Chiara ;

Sala, Valentina ;

Martini, Miriam ;

Ferrero, Giovanni Battista ;

Hirsch, Emilio .

CANCERS, 2017, 9 (04)

[7] The PI3K/AKT/mTOR interactive pathway [J].

Ersahin, Tulin ;

Tuncbag, Nurcan ;

Cetin-Atalay, Rengul .

MOLECULAR BIOSYSTEMS, 2015, 11 (07) :1946-1954

[8] PI3K/Akt and apoptosis: size matters [J].

Franke, TF ;

Hornik, CP ;

Segev, L ;

Shostak, GA ;

Sugimoto, C .

ONCOGENE, 2003, 22 (56) :8983-8998

[9] Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity [J].

Fuse, Shinichiro ;

Suzuki, Kensuke ;

Kuchimaru, Takahiro ;

Kadonosono, Tetsuya ;

Ueda, Hiroki ;

Sato, Shinichi ;

Kizaka-Kondoh, Shinae ;

Nakamura, Hiroyuki .

BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (01)

[10] Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)-ones and 4, 6-disubstituted-1, 2, 3, 4-tetrahydroquinazolin-2H-ones [J].

Gawad, Nagwa M. Abdel ;

Georgey, Hanan H. ;

Youssef, Riham M. ;

El-Sayed, Nehad A. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (12) :6058-6067

← 1 2 3 4 →